|
AU4128089A
(en)
|
1988-09-15 |
1990-03-22 |
Rorer International (Overseas) Inc. |
Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
|
|
US7060808B1
(en)
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
|
EP1585768A2
(en)
|
2003-01-23 |
2005-10-19 |
Genentech, Inc. |
Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
|
|
CA2777825A1
(en)
|
2009-10-28 |
2011-05-19 |
Abbott Biotherapeutics Corp. |
Anti-egfr antibodies and their uses
|
|
ES2993140T3
(en)
|
2010-04-02 |
2024-12-23 |
Amunix Pharmaceuticals Inc |
Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
|
|
US8557961B2
(en)
|
2010-04-02 |
2013-10-15 |
Amunix Operating Inc. |
Alpha 1-antitrypsin compositions and methods of making and using same
|
|
CN103068847B
(zh)
*
|
2010-08-24 |
2019-05-07 |
罗切格利卡特公司 |
可活化的双特异性抗体
|
|
CN103382223B
(zh)
|
2012-04-01 |
2015-06-10 |
上海益杰生物技术有限公司 |
针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
|
|
JP6509724B2
(ja)
|
2012-04-20 |
2019-05-08 |
アプティーボ リサーチ アンド デベロップメント エルエルシー |
Ｃｄ３結合ポリペプチド
|
|
CN110078827A
(zh)
*
|
2012-04-27 |
2019-08-02 |
西托姆克斯治疗公司 |
结合表皮生长因子受体的可活化的抗体其使用方法
|
|
JP6092649B2
(ja)
|
2013-02-15 |
2017-03-08 |
キヤノン株式会社 |
演算装置、アレイ型演算装置およびその制御方法、情報処理システム
|
|
WO2015066279A2
(en)
*
|
2013-10-30 |
2015-05-07 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
|
JP2016538275A
(ja)
|
2013-11-04 |
2016-12-08 |
グレンマーク ファーマシューティカルズ， エセ．アー． |
Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃ ｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造
|
|
US10519251B2
(en)
|
2013-12-30 |
2019-12-31 |
Epimab Biotherapeutics, Inc. |
Fabs-in-tandem immunoglobulin and uses thereof
|
|
CA2955947A1
(en)
*
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
|
US11773166B2
(en)
|
2014-11-04 |
2023-10-03 |
Ichnos Sciences SA |
CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
|
|
CN105820248A
(zh)
|
2015-01-07 |
2016-08-03 |
上海张江生物技术有限公司 |
一种新型抗egfr单克隆抗体的制备方法及应用
|
|
US9708412B2
(en)
|
2015-05-21 |
2017-07-18 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
|
EP3322735A4
(en)
|
2015-07-15 |
2019-03-13 |
Zymeworks Inc. |
ACTIVE CONJUGATED BIS-SPECIFIC ANTIGEN-BONDING CONSTRUCTS
|
|
CN116333130A
(zh)
|
2016-05-24 |
2023-06-27 |
英斯梅德股份有限公司 |
抗体及其制备方法
|
|
WO2019067015A1
(en)
*
|
2017-09-29 |
2019-04-04 |
City Of Hope |
RECEPTORS OF CHIMERIC ANTIGENS AND BISPECIFIC ANTIBODIES FOR THE TREATMENT OF COAT CELL LYMPHOMA
|
|
JP2022535924A
(ja)
|
2019-06-06 |
2022-08-10 |
ジャナックス セラピューティクス，インク． |
腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法
|
|
MX2021015882A
(es)
|
2019-06-26 |
2022-04-18 |
Amunix Pharmaceuticals Inc |
Fragmentos de unión a antígeno egfr y composiciones que los comprenden.
|
|
CA3143519A1
(en)
|
2019-06-26 |
2020-12-30 |
Volker Schellenberger |
Cd3 antigen binding fragments and compositions comprising same
|
|
KR20210043475A
(ko)
|
2019-10-10 |
2021-04-21 |
주식회사 와이바이오로직스 |
다중 특이적 융합 단백질 및 이의 용도
|
|
MX2023013382A
(es)
|
2020-04-04 |
2024-01-30 |
Janux Therapeutics Inc |
Composiciones y metodos relacionados con anticuerpos activados contra tumores dirigidos a egfr y antigenos de celulas efectoras.
|
|
EP4631977A3
(en)
|
2020-08-11 |
2025-12-10 |
Janux Therapeutics, Inc. |
Cleavable linker compositions and methods
|
|
WO2022094299A2
(en)
|
2020-10-30 |
2022-05-05 |
Janux Therapeutics, Inc. |
Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof
|
|
US20240043536A1
(en)
|
2020-12-08 |
2024-02-08 |
Janux Therapeutics, Inc. |
Peptide compositions and methods for anti-cd3 binding domains
|
|
US20240254241A1
(en)
|
2021-05-11 |
2024-08-01 |
Janux Therapeutics, Inc. |
Antibodies targeting egfr and cd3 and uses thereof
|
|
EP4615514A2
(en)
|
2022-11-10 |
2025-09-17 |
Janux Therapeutics, Inc. |
Antibodies targeting egfr and cd3 and uses thereof
|
|
WO2024100451A2
(en)
|
2022-11-11 |
2024-05-16 |
Janux Therapeutics, Inc. |
Compositions and uses of tumor activated antibodies targeting egfr and effector cell antigens
|